US-based healthcare company Viz.ai has announced a strategic collaboration with Swiss drugmaker Novartis to enhance cancer care through AI-powered solutions.
The partnership focuses on developing workflows within the Viz Oncology Suite to improve the timely diagnosis and stratification of prostate and breast cancer patients.
It aims to address the delays in cancer diagnosis and treatment, which often stem from fragmented systems and manual reviews, using AI.
Novartis US oncology head Rodney Gillespie said: “Earlier diagnosis and interventions can positively impact patient outcomes.
“At Novartis, we lead the industry in fostering bold partnerships and initiatives that support early screening and diagnosis; we are also leveraging innovative, data-driven technologies to help connect patients with appropriate care as quickly as possible.
“By sharing key insights with Viz.ai, we will develop AI-powered solutions to quickly help reach patients who could benefit from guideline-based targeted treatments for prostate and breast cancer, helping significantly expedite their care.”
As part of the initiative, Viz.ai will introduce two AI-powered solutions, Viz Prostate Cancer and Viz Breast Cancer.
The Viz Prostate Cancer solution will streamline patient identification for guideline-based treatment and facilitate timely referrals to specialists.
Viz Breast Cancer will support breast oncologists by automating patient reviews, aggregating risk data and coordinating care among multidisciplinary teams.
Viz.ai CEO and co-founder Chris Mansi said: “We are excited to be partnering with Novartis, an innovative medicines company and a leader in oncology, to accelerate access to timely, guideline-based care for patients facing prostate and breast cancer.
“This collaboration is part of our broader strategic expansion into oncology, furthering Viz.ai’s mission to fundamentally transform healthcare through intelligent care coordination.”
Viz.ai is a pioneer in AI algorithms and machine learning, enhancing diagnosis and care speed across over 1,700 hospitals in the US and Europe.
Last month, the company entered a multi-year collaboration with pharmaceutical companies, Sanofi and Regeneron, to implement an AI-driven workflow solution for COPD.
